FTC Supports NAD, But Does Not Mirror The CBBB Division’s Transparency
This article was originally published in The Tan Sheet
Executive Summary
The federal and private entities monitoring dietary supplement health claims are not created equal, says attorney Anthony L. Young
You may also be interested in...
FTC Settlement Looks To Ground Airborne Claims
Under a settlement with the Federal Trade Commission announced Aug. 14, the maker of Airborne dietary supplement products must cease unsubstantiated health-related claims and contribute up to $6.5 million to an existing consumer redress fund
Making Regulatory Decisions Not Part Of NAD’s Job Description
The National Advertising Division says it is not taking on a regulatory role to determine whether a product should be considered a drug or a supplement while it continues recommending whether advertising for OTC drugs or supplements is false or misleading
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.